← Back to front page
United States · Business magazines · Quartz

Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront

Published by Quartz · United States 23 min ago
Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront
Quartz

Detailed summary

Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324

Read the full article on Quartz Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)

Also worth reading